Physician Data Query

Last uploaded: August 27, 2019
Preferred Name

blinatumomab

Synonyms

bispecific T-cell engager MT103

Definitions

A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528" NCI Thesaurus)

ID

http://purl.bioontology.org/ontology/PDQ/CDR0000487684

altLabel

bispecific T-cell engager MT103

Blincyto

anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103

MEDI-538

MT-103

cui

C3864946

C3853840

C4276437

C3853839

DATE FIRST PUBLISHED

2006-06-02

Date last modified

2008-11-21

definition

A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62528" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62528" NCI Thesaurus)

LT

TRD

NCI ID

C62528

notation

CDR0000487684

ORIG STY

Drug/agent

prefLabel

blinatumomab

tui

T116

T129

T121

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62528 NCIT LOOM
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62528 NCIT LOOM
http://purl.bioontology.org/ontology/UATC/L01XC19 ATC CUI
http://purl.bioontology.org/ontology/UATC/L01XC19 ATC LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/774173007 SNOMEDCT CUI
http://purl.bioontology.org/ontology/RXNORM/1597263 RXNORM CUI
http://purl.bioontology.org/ontology/NDFRT/N0000191284 NDFRT CUI
http://purl.bioontology.org/ontology/NDFRT/N0000191284 NDFRT LOOM
http://purl.bioontology.org/ontology/NDDF/015799 NDDF CUI
http://purl.bioontology.org/ontology/NDDF/015799 NDDF LOOM
http://purl.obolibrary.org/obo/DRON_00730842 DRON LOOM
http://purl.obolibrary.org/obo/DRON_00730842 DRON LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#C510808 RH-MESH LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/716122004 SNOMEDCT CUI
http://purl.bioontology.org/ontology/SNOMEDCT/716122004 SNOMEDCT LOOM
http://purl.bioontology.org/ontology/RXNORM/1597258 RXNORM CUI
http://purl.bioontology.org/ontology/RXNORM/1597258 RXNORM LOOM
http://purl.bioontology.org/ontology/MESH/C510808 MESH CUI
http://purl.bioontology.org/ontology/MESH/C510808 MESH CUI
http://purl.bioontology.org/ontology/MESH/C510808 MESH CUI
http://purl.bioontology.org/ontology/MESH/C510808 MESH LOOM
http://purl.bioontology.org/ontology/SCTSPA/716122004 SCTSPA CUI
http://purl.bioontology.org/ontology/VANDF/4033958 VANDF CUI
http://purl.bioontology.org/ontology/VANDF/4033958 VANDF LOOM